Scientific Advice meetings are a mechanism to improve communications between drug developers and regulators during the drug-development process. While standard practice for industry, the benefits provided by these meetings are under-utilised by academia. In the context of drug repurposing, can scientific advice, as part of a proposed new R&D tax credits scheme, help to unblock some of the obstacles in the way to clinical adoption?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V. & Sukhatme, V. P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 8, 442 (2014).
Bertolini, F., Sukhatme, V. P. & Bouche, G. Drug repurposing in oncology — patient and health systems opportunities. Nat. Rev. Clin. Oncol. 12, 732–742 (2015).
Davies, E. H., Fulton, E., Brook, D. & Hughes, D. A. Affordable orphan drugs: a role for not-for-profit organizations. Br. J. Clin. Pharmacol. http://dx.doi.org/10.1111/bcp.13240 (2017).
UK Parliament. Off-patent Drugs Bill 2015–2016. Parliament.uk http://services.parliament.uk/bills/2015-16/offpatentdrugs.html (2015).
Hadji, P. et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann. Oncol. 27, 379–390 (2016).
Pasquier, E. et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine 6, 87–95 (2016).
Chow, W. et al. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatol. 151, 1226–1229 (2015).
Regnstrom, J. et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39–48 (2010).
Hofer, M. P. et al. Regulatory watch: impact of scientific advice from the European Medicines Agency. Nat. Rev. Drug Discov. 14, 302–303 (2015).
Yordanov, Y. et al. Avoidable waste of research related to inadequate methods in clinical trials. BMJ 350, h809 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Pantziarka, P. Scientific advice — is drug repurposing missing a trick?. Nat Rev Clin Oncol 14, 455–456 (2017). https://doi.org/10.1038/nrclinonc.2017.69
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.69
This article is cited by
-
Design, Development, In Silico, and In Vitro Characterization of Camptothecin-Loaded Mixed Micelles: In Vitro Testing of Verapamil and Ranolazine for Repurposing as Coadjuvant Therapy in Cancer
Journal of Pharmaceutical Innovation (2023)
-
The evidence for repurposing anti-epileptic drugs to target cancer
Molecular Biology Reports (2023)
-
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Journal of Hematology & Oncology (2022)
-
Repositioning Generic Drugs: Empirical Findings and Policy Implications
IIC - International Review of Intellectual Property and Competition Law (2022)
-
Signature-based approaches for informed drug repurposing: targeting CNS disorders
Neuropsychopharmacology (2021)
